Elan's EL-10 for AIDS
Elan's EL-10 for AIDS: First U.S. clinical trials of the oral copolymer adsorbate of DHEA began March 2 in San Francisco. A placebo-controlled trial of EL-10 is already in progress in Amsterdam, and a multi-center study proposal has been submitted to Canadian authorities, Elan said. The company obtained exclusive worldwide rights to EL-10 from microbiologist Patrick Prendergast and his company Colthurst Ltd.
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.